Table 1.
Clinical and biochemical characteristics of cirrhotic patients
| Variable | Total (n = 100) | NGT (n = 30) | SAGT (n = 70) |
| Age, yr | 53.9 ± 11.8 | 49.0 ± 12.0 | 56.0 ± 11.11 |
| BMI, kg/m2 | 26.9 ± 4.2 | 26.4 ± 4.40 | 27.21 ± 4.15 |
| Males | 60 (60) | 18 (60) | 42 (60) |
| Etiology: Alcohol | 47 (47) | 14 (46.6) | 33 (47.1) |
| HBV | 4 (4) | 1 (3.3) | 3 (4.2) |
| HCV | 13 (13) | 2 (6.6) | 11 (15.7) |
| Autoimmunity | 10 (10) | 3 (10) | 7 (10) |
| Cryptogenic | 26 (26) | 10 (33.3) | 16 (22.8) |
| Liver biopsy | 44 (44) | 13 (43.3) | 31 (44.2) |
| Length of LC, mo | 21.6 + 27.6 | 21.4 ± 30.6 | 21.7 ± 33.2 |
| Hemoglobin, g/dL | 11.8 ± 2.3 | 11.6 ± 2.1 | 11.9 ± 2.3 |
| Platelets, × mm3 | 128140 ± 89501 | 159186 ± 112108 | 114834 ± 73269 |
| INR | 1.3 ± 0.3 | 1.2 ± 0.3 | 1.36 ± 0.32 |
| Creatinine, mg/dL | 0.8 ± 0.2 | 0.90 ± 0.33 | 0.83 ± 0.2 |
| Albumin, g/dL | 3.2 ± 0.73 | 3.33 ± 0.71 | 3.21 ± 0.74 |
| ALT, UI/L | 46.5 ± 40.8 | 48.9 ± 53.9 | 45.4 ± 34.0 |
| Total bilirubin, mg/dL | 1.71 ± 0.90 | 1.55 ± 0.88 | 1.78 ± 0.91 |
| Fasting plasma insulin, μU/mL | 15.9 ± 10.2 | 11.9 ± 7.6 | 18.2 ± 113 |
| HOMA2 score | 2.67 ± 1.6 | 2.36 ± 1.46 | 4.6 ± 3.34 |
| Child-Pugh A | 47 (47) | 15 (50) | 32 (45.7) |
| B | 53 (53) | 15 (50) | 38 (54.2) |
| Child Pugh score | 6.8 ± 1.8 | 6.5 ± 1.61 | 6.82 ± 1.67 |
| MELD score | 8.94 ± 4.8 | 8.3 ± 5.2 | 9.21 ± 4.63 |
| Survival, d | 1237 | 1448 | 1116 |
| (990-1925) | (1256-1925) | (990-1790)5 |
Data are expressed as absolute numbers (percentage) or mean ± SD.
1
P = 0.003;
2
P = 0.025;
3
P = 0.03;
4
P = 0.009;
5
P = 0.045. NGT: Normal glucose tolerance; SAGT: Subclinical abnormal glucose tolerance; HOMA: Homeostatic model assessment; LC: Liver cirrhosis. BMI: Body mass index; MELD: Model for End-Stage Liver Disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; INR: International normalized ratio; ALT: Alanine transaminase.